MUMBAI, India, Sept. 14 -- Intellectual Property India has published a patent application (202611088112 A) filed by Chitkara University on July 19, 2026, for Targeted Nanoformulation Comprising Thymosin Alpha-1 And Phytochemicals For Immunomodulatory Management Of Rheumatoid Arthritis.
Inventors include Dr. Indu Bala; Dr. Pallavi Aggarwal; Dr. Mansi Chitkara; and Dr. Pranav Kumar Prabhakar.
The application for the patent was published on September 11, 2026, under issue no. 37/2026.
Abstract: The present invention relates to a targeted nanoformulation for immunomodulatory management of rheumatoid arthritis. The nanoformulation comprises a nanocarrier system incorporating Thymosin Alpha-1 and one or more phytochemicals selected from curcumin, quercetin, epigallocatechin gallate, luteolin, kaempferol, or combinations thereof. The nanocarrier may further comprise targeting ligands including hyaluronic acid and mannose and optionally stimuli-responsive materials. The nanoformulation enables targeted delivery of Thymosin Alpha-1 and phytochemicals to inflamed synovial tissue
Disclaimer: Curated by HT Syndication.
